Healthy men help scientists track how cenerimod exits the body
NCT ID NCT02914223
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study gave a single dose of a radiolabeled drug called cenerimod to 6 healthy men aged 45-65. The goal was to see how quickly and by what routes (urine, feces, breath) the drug leaves the body. It is a Phase 1 trial with no treatment benefit, purely to gather information for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cenerimod (a drug being tested for immune-related conditions)
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PRA Health Science
Groningen, 9728 NZ, Netherlands